Literatuur
- Conroy T. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. The New England journal of medicine. 2018; 379(25): 2395-406
- Neoptolemos JP et al. European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017; 389(10073): 1011-24
- Conroy T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England journal of medicine. 2011; 364(19): 1817-25
- Von Hoff DD et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. The New England journal of medicine. 2013; 369(18): 1691-703
- Golan T. et al. Maintainance olaparib for germline BRCA mutated metastatic pancreatic cancer. The New England journal of medicine. 2019; 381(4): 317-27
- Wang-Gillam A et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019 Feb; 108: 78-87
- Kindler et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol 2022; 40: 3929-3939
Commissie BOM adviezen
Ga naar de commisie BOM adviezen over pancreascarcinoom.
Richtlijnen
Ga naar de richtlijn Pancreascarcinoom in de FMS richtlijnendatabase.